CPT 82088: Aldosterone Quantitative Assay
Commercial payers pay $74 on average nationally for this procedure.
CPT code 82088 describes a quantitative laboratory assay to measure aldosterone concentration, typically performed on serum, plasma, or urine to evaluate suspected primary or secondary hyperaldosteronism; this is a clinical laboratory service (endocrine/metabolic testing) commonly ordered from outpatient clinics or hospital laboratories and performed in a clinical laboratory or hospital lab setting.
For related coverage guidance, see recent payer policy updates: Salivary Hormone Testing, Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing, Bone Turnover Markers Testing.
Customize your policy alerts
Sign up for cpt 82088 policy alerts
Get alerted when payer policies referencing 82088 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
For CPT 82088 the average commercial benchmark (BUCA) sits at $73.90, positioning national commercial reimbursement near the mid-range among large payers. Blue Cross Blue Shield exhibits the highest mean at $100.50 and the largest spread between the 25th and 75th percentiles ($61.60 to $122.60), while Aetna and Cigna have lower means of $35.10 and $45.10 respectively. UnitedHealth Group’s mean is $35.40, with a notably low median of $24.50 versus its mean, suggesting skew toward higher outliers.
Measuring dispersion as P75 minus P25, Blue Cross Blue Shield is the widest with a spread of $60.10, indicating greater regional or contractual variability; BUCA’s interquartile spread is $44.40, reflecting moderate commercial variability around the $73.90 average. The tightest spreads are with UnitedHealth Group ($19.70) and Cigna ($34.10), implying relatively more consistency in negotiated commercial rates for those payers.